{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:03:00Z","timestamp":1787065380893,"version":"build-2736575974"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity Science &amp;amp; Practice"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Injectable GLP\u20101 drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro, a dual GLP\u20101 and GIP receptor agonist) can help individuals living with obesity to lose weight. UK guidelines currently recommend semaglutide and other injectable GLP\u20101 drugs are prescribed in specialist (Tier 3) multidisciplinary weight management services, and other settings. The study aimed to explore the views of healthcare professionals, working within a specialist weight management service that was not yet prescribing injectable GLP\u20101 drugs, about these drugs being prescribed in their service in the future.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In\u2010depth interviews were conducted with 11 healthcare professionals; thematic analysis was used to identify themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen\u00a0main themes were identified within four theme clusters.\n                      <jats:italic>Knowledge<\/jats:italic>\n                      : (1) knowledge sources; (2) levels of current understanding.\n                      <jats:italic>Perceived benefits<\/jats:italic>\n                      : the drugs (3) might increase patients' confidence in their ability to lose weight and (4) provide a valuable middle ground treatment option between interpersonal behavioral support and bariatric surgery.\n                      <jats:italic>Concerns<\/jats:italic>\n                      : (5) patients might gain weight when they stop taking the drugs; the drugs might (6) mask behavioral patterns, (7) decrease patients' engagement with interpersonal behavior change support, and (8) have mental health risks.\n                      <jats:italic>Service provision considerations<\/jats:italic>\n                      : providing interpersonal behavior change support (9)\u00a0before, (10) alongside, and (11) after stopping drug prescriptions were provided, (12) the drug prescription pathway is experimental, and (13) the role of healthcare professionals in specialist weight management services is evolving.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The findings highlight several areas for further research and practice, including how specialist weight management service teams might integrate interpersonal behavioral support and injectable GLP\u20101 drug prescriptions to best help patients in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/osp4.70130","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:26:32Z","timestamp":1773314792000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Attitudes Toward Injectable GLP\u20101 Drugs for Obesity Treatment: A Qualitative Interview Study With Healthcare Professionals"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7368-1769","authenticated-orcid":false,"given":"Raluca C.","family":"Capaian","sequence":"first","affiliation":[{"name":"School of Psychology University of Surrey  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillippa","family":"Lally","sequence":"additional","affiliation":[{"name":"School of Psychology University of Surrey  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia C.","family":"Sanderson","sequence":"additional","affiliation":[{"name":"School of Psychology University of Surrey  Guildford UK"},{"name":"Department of Biostatistics and Health Informatics, Psychology and Neuroscience, King's College London Institute of Psychiatry  London UK"},{"name":"Department of Behavioural Science and Health University College London  London UK"},{"name":"NIHR Mental Health Translational Research Collaboration (MH\u2010TRC) Mission  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)02750\u20102"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010016\u20100221\u2010z"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jhn.12732"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12601"},{"key":"e_1_2_11_6_1","unstructured":"Group NEaPHEW Report of the Working Group Into: Joined up Clinical Pathways for Obesity (2014)."},{"key":"e_1_2_11_7_1","unstructured":"NICE 1 Recommendations Weight Management: Lifestyle Services for Overweight or Obese Adults Guidance (2014) https:\/\/www.nice.org.uk\/guidance\/ph53\/chapter\/recommendations."},{"key":"e_1_2_11_8_1","volume-title":"1 Recommendations Semaglutide for Managing Overweight and Obesity | Guidance","author":"NICE","year":"2023"},{"key":"e_1_2_11_9_1","unstructured":"N. D The Guardian. Online UK Pharmacies Prescribing Weight Loss Jabs to People with Healthy BMI (2023)."},{"key":"e_1_2_11_10_1","unstructured":"M. HpR. Agency GLP\u20101 Medicines for Weight Loss and Diabetes: What You Need to Know (2026)."},{"key":"e_1_2_11_11_1","unstructured":"NICE 2 Information About Tirzepatide Tirzepatide for Managing Overweight and Obesity Guidance (2024) https:\/\/www.nice.org.uk\/guidance\/ta1026\/chapter\/2\u2010Information\u2010about\u2010tirzepatide."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kaae022"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.70251"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12666"},{"key":"e_1_2_11_15_1","volume-title":"Introducing Qualitative Research in Psychology","author":"Willing C.","year":"2022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/2159676x.2019.1628806"},{"key":"e_1_2_11_17_1","first-page":"184","volume-title":"Transforming Qualitative Information: Thematic Analysis and Code Development","author":"Boyatzis R. E.","year":"1998"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11135\u2010021\u201001182\u2010y"},{"key":"e_1_2_11_19_1","first-page":"57","volume-title":"APA Handbooks in Psychology\u00ae","author":"Braun V.","year":"2012"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp.2025.0065"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24290"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.756"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2022.113967"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40337\u2010023\u201000797\u2010w"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2022.2147326"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080"},{"key":"e_1_2_11_30_1","unstructured":"Administration UFaD Update on Fda\u2019s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity (2024)."},{"key":"e_1_2_11_31_1","volume-title":"Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u201311 April 2024","author":"European Medicines A","year":"2024"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.08.010"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101962"},{"key":"e_1_2_11_34_1","volume-title":"Why Fat Jabs \u201cMean UK Obesity Rates May Have Peaked","author":"K P.","year":"2025"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","unstructured":"S. E.Jackson J.Brown C.Llewellyn O.Mytton andL.Shahab Prevalence of Use and Interest in Using Glucagon\u2010like peptide\u20101 Receptor Agonists for Weight Loss: A Population Study in Great Britain (2025).","DOI":"10.1101\/2025.06.06.25329114"},{"key":"e_1_2_11_36_1","unstructured":"N.Triggle NHS Gets 12 Years to Roll out New weight\u2010loss Drug Mounjaro (2024)."}],"container-title":["Obesity Science &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/osp4.70130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/osp4.70130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/osp4.70130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:01:49Z","timestamp":1777291309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/osp4.70130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/osp4.70130"],"URL":"https:\/\/doi.org\/10.1002\/osp4.70130","archive":["Portico"],"relation":{},"ISSN":["2055-2238","2055-2238"],"issn-type":[{"value":"2055-2238","type":"print"},{"value":"2055-2238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"2025-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70130"}}